HIV and hepatitis C coinfection

Journal of Gastroenterology and Hepatology (Australia)

Volumn 23, Issue 7 PT1, 2008, Pages 1000-1008

  Matthews, Gail V ^a   Dore, Gregory J ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Antiretroviral therapy; Hepatitis C; HIV; Natural history; Pegylated interferon

Indexed keywords

AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; ERYTHROPOIETIN; LOPINAVIR; NEVIRAPINE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTEINASE INHIBITOR; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ANEMIA; DECOMPENSATED LIVER CIRRHOSIS; DEPRESSION; DISEASE COURSE; DRUG CONTRAINDICATION; EARLY DIAGNOSIS; FATTY LIVER; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTIC ACIDOSIS; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TOXICITY; METABOLIC ACIDOSIS; MITOCHONDRIAL TOXICITY; MIXED INFECTION; PANCREATITIS; PRIORITY JOURNAL; SEROLOGY; SHORT SURVEY; STANDARD; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD;

EID: 47649114060     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2008.05489.x     Document Type: Short Survey

References (93)

1. Amin J, Kaye M, Skidmore S, Pillay D, Cooper DA, Dore GJ. HIV and hepatitis C coinfection within the CAESAR study. HIV Med. 2004 5 : 174 9.
2. Rockstroh JK, Mocroft A, Soriano V et al. Influence of Hepatitis C Virus Infection on HIV-1 Disease Progression and Response to Highly Active Antiretroviral Therapy. J. Infect. Dis. 2005 192 : 992 1002.
3. Wright TL, Hollander H, Pu X et al. Hepatitis C in HIV-infected patients with and without AIDS: prevalence and relationship to patient survival. Hepatology 1994 20 : 1152 5.
4. Zhou J, Dore GJ, Zhang F, Lim PL, Chen YM Hepatitis B and C virus coinfection in The TREAT Asia HIV Observational Database. J. Gastroenterol. Hepatol. 2007 22 : 1510 8.
5. Aceijas C, Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int. J. Drug Policy 2007 18 : 352 8.
6. Garten RJ, Zhang J, Lai S, Liu W, Chen J, Yu XF. Coinfection with HIV and hepatitis C virus among injection drug users in southern China. Clin. Infect. Dis. 2005 41 (Suppl. 1 S18 24.
7. Garten R, Zhang J, Liu W, Chen J, Yu X-F. Coinfection with HIV and hepatitis C virus among injection drug users in Southern China. Clin. Infect. Dis. 2005 41 (Suppl. 1 S18 24.
8. Qian HZ, Vermund SH, Kaslow RA et al. Coinfection with HIV and hepatitis C virus in former plasma/blood donors: challenge for patient care in rural China. AIDS 2006 20 : 1429 35.
9. Saha MK, Chakrabarti S, Panda S et al. Prevalence of HCV & HBV infection amongst HIV seropositive intravenous drug users & their non-injecting wives in Manipur India. Indian J. Med. Res. 2000 111 : 37 9.
10. Sarkar K, Bal B, Mukherjee R et al. Epidemic of HIV coupled with hepatitis C virus among injecting drug users of Himalayan West Bengal, Eastern India, Bordering Nepal, Bhutan, and Bangladesh. Subst. Use Misuse 2006 41 : 341 52.
11. Hansurabhanon T, Jiraphongsa C, Tunsakun P et al. Infection with hepatitis C virus among intravenous-drug users: prevalence, genotypes and risk-factor-associated behaviour patterns in Thailand. Ann. Trop. Med. Parasitol. 2002 96 : 615 25.
12. Chanbancherd P, Paris RM, Torugsa K et al. High frequency of HIV-1 and hepatitis C coinfection among young Thai men: evidence for a changing pattern of HIV transmission in Thailand. Southeast Asian J. Trop. Med. Public Health 2003 34 : 580 2.
13. Walsh N, Higgs P, Crofts N. Recognition of hepatitis C virus coinfection in HIV-positive injecting drug users in Asia. J. Acquir. Immune Defic. Syndr. 2007 45 : 363 5.
14. Chen YD, Liu MY, Yu WL et al. Hepatitis C virus infections and genotypes in China. Hepatobiliary Pancreat. Dis. Int. 2002 1 : 194 201.
15. Lee CM, Lu SN, Hung CH et al. Hepatitis C virus genotypes in southern Taiwan: prevalence and clinical implications. Trans. R. Soc. Trop. Med. Hyg. 2006 100 : 767 74.
16. Kim YS, Ahn YO, Lee HS. Risk factors for hepatitis C virus infection among Koreans according to the hepatitis C virus genotype. J. Korean Med. Sci. 2002 17 : 187 92.
17. Verachai V, Phutiprawan T, Theamboonlers A et al. Prevalence and genotypes of hepatitis C virus infection among drug addicts and blood donors in Thailand. Southeast Asian J. Trop. Med. Public Health 2002 33 : 849 51.
18. Kanistanon D, Neelamek M, Dharakul T, Songsivilai S. Genotypic distribution of hepatitis C virus in different regions of Thailand. J. Clin. Microbiol. 1997 35 : 1772 6.
19. Hissar SS, Goyal A, Kumar M et al. Hepatitis C virus genotype 3 predominates in North and Central India and is associated with significant histopathologic liver disease. J. Med. Virol. 2006 78 : 452 8.
20. Singh S, Malhotra V, Sarin SK. Distribution of hepatitis C virus genotypes in patients with chronic hepatitis C infection in India. Indian J. Med. Res. 2004 119 : 145 8.
21. Zhang L, Chen Z, Cao Y et al. Molecular characterization of human immunodeficiency virus type 1 and hepatitis C virus in paid blood donors and injection drug users in china. J. Virol. 2004 78 : 13591 9.
22. Thomas DL, Astemborski J, Rai RM et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000 284 : 450 6.
23. Mehta SH, Cox A, Hoover DR et al. Protection against persistence of hepatitis C. Lancet 2002 359 : 1478 83.
24. Cribier B, Rey D, Schmitt C, Lang JM, Kirn A, Stoll-Keller F. High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV. AIDS 1995 9 : 1131 6.
25. Thomas DL, Shih JW, Alter HJ et al. Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J. Infect. Dis. 1996 174 : 690 5.
26. Sherman KE, O'Brien J, Gutierrez AG et al. Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infections. J. Clin. Microbiol. 1993 31 : 2679 82.
27. Soto B, Sanchez-Quijano A, Rodrigo L et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J. Hepatol. 1997 26 : 1 5.
28. Polis CB, Shah SN, Johnson KE, Gupta A. Impact of maternal HIV coinfection on the vertical transmission of hepatitis C virus: a meta-analysis. Clin. Infect. Dis. 2007 44 : 1123 31.
29. Weber R, Sabin CA, Friis-Moller N et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch. Intern. Med. 2006 166 : 1632 41.
30. Graham CS, Baden LR, Yu E et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin. Infect. Dis. 2001 33 : 562 9.
31. Benhamou Y, Bochet M, Di M, V et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999 30 : 1054 8.
32. Mohsen AH, Easterbrook PJ, Taylor C et al. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut 2003 52 : 1035 40.
33. Eyster ME, Sherman KE, Goedert JJ, Katsoulidou A, Hatzakis A. Prevalence and changes in hepatitis C virus genotypes among multitransfused persons with hemophilia. The Multicenter Hemophilia Cohort Study. J. Infect. Dis. 1999 179 : 1062 9.
34. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N. Engl. J. Med. 1999 341 : 22 6.
35. Nunez M. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J. Hepatol. 2006 44 (Suppl. 1 S132 9.
36. Sanchez-Conde M, Berenguer J, Miralles P et al. Liver biopsy findings for HIV-infected patients with chronic hepatitis C and persistently normal levels of alanine aminotransferase. Clin. Infect. Dis. 2006 43 : 640 4.
37. Bica I, McGovern B, Dhar R et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin. Infect. Dis. 2001 32 : 492 7.
38. Soriano V, Garcia-Samaniego J, Valencia E, Rodriguez-Rosado R, Munoz F, Gonzalez-Lahoz J. Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. Eur. J. Epidemiol. 1999 15 : 1 4.
39. Rosenthal E, Poiree M, Pradier C et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS 2003 17 : 1803 9.
40. Salmon-Ceron D, Lewden C, Morlat P et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J. Hepatol. 2005 42 : 799 805.
41. Brau N, Xiao P, Naqvi Z et al. Hepatocellular carcinoma in 40 HIV/HCV coinfected versus 50 HCV-monoinfected patients. North American HCC in HIV Study Group. In: 3rd IAS Conference on HIV pathogenesis and treatment; 24-27 July; Rio de Janeiro, Brazil, 2005.
42. Puoti M, Bruno R, Soriano V et al. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS 2004 18 : 2285 93.
43. Benhamou Y, Di Martino V, Bochet M et al. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 2001 34 : 283 7.
44. Quirishi N, Kreuzberg C, Luchters G et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIv and hepatitis C virus coinfection. Lancet 2003 362 : 1708 13.
45. Marine-Barjoan E, Saint-Paul MC, Pradier C et al. Impact of antiretroviral treatment on progression of hepatic fibrosis in HIV/hepatitis C virus coinfected patients. AIDS 2004 18 : 2163 70.
46. Stuver S, Fleming C, Nunes D et al. Predictors of liver disease progression in a cohort of HIV/HCV coinfected drug users. In: 12th Conference on Retroviruses and Opportunistic Infections; 22-25 February; Boston, Massachusetts, USA, 2005.
47. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL Hepatitis C and progression of HIV disease. JAMA 2002 288 : 199 206.
48. Law P, Duncombe C, Mahanontharit A et al. Impact of viral hepatitis coinfection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS 2004 18 : 1169 77.
49. Hung CC, Chen MY, Hsieh SM, Hsiao CF, Sheng WH, Chang SC. Impact of chronic hepatitis C infection on outcomes of patients with an advanced stage of HIV-1 infection in an area of low prevalence of coinfection. Int. J. STD AIDS 2005 16 : 42 8.
50. Greub G, Ledergerber B, Battegay M et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000 356 : 1800 5.
51. Anderson KB, Guest JL, Rimland D Hepatitis C virus coinfection increases mortality in HIV-infected patients in the highly active antiretroviral therapy era: data from the HIV Atlanta VA Cohort Study. Clin. Infect. Dis. 2004 39 : 1507 13.
52. Stebbing J, Waters L, Mandalia S, Bower M, Nelson M, Gazzard B Hepatitis C virus infection in HIV type 1-infected individuals does not accelerate a decrease in the CD4+ cell count but does increase the likelihood of AIDS-defining events. Clin. Infect. Dis. 2005 41 : 906 11.
53. Miller MF, Haley C, Koziel MJ, Rowley CF. Impact of hepatitis C virus on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: a meta-analysis. Clin. Infect. Dis. 2005 41 : 713 20.
54. Taya N, Torimoto Y, Shindo M, Hirai K, Hasebe C, Kohgo Y. Fas-mediated apoptosis of peripheral blood mononuclear cells in patients with hepatitis C. Br. J. Haematol. 2000 110 : 89 97.
55. Laskus T, Radkowski M, Piasek A et al. Hepatitis C virus in lymphoid cells of patients coinfected with human immunodeficiency virus type 1: evidence of active replication in monocytes/ macrophages and lymphocytes. J. Infect. Dis. 2000 181 : 442 8.
56. Hansjee N, Kaufmann GR, Strub C, Weber R, Battegay M, Erb P. Persistent apoptosis in HIV-1-infected individuals receiving potent antiretroviral therapy is associated with poor recovery of CD4 T lymphocytes. J. Acquir. Immune Defic. Syndr. 2004 36 : 671 7.
57. Chu CJ, Lee SD. Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment. J. Gastroenterol. Hepatol. 2008 23 : 512 20.
58. Macias J, Giron-Gonzalez JA, Gonzalez-Serrano M et al. Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes. Gut 2006 55 : 409 14.
59. Myers RP, Benhamou Y, Imbert-Bismut F et al. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus coinfected patients. AIDS 2003 17 : 721 5.
60. de Ledinghen V, Douvin C, Kettaneh A et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J. Acquir. Immune Defic. Syndr. 2006 41 : 175 9.
61. Puoti M, Spinetti A, Ghezzi A et al. Mortality for liver disease in patients with HIV infection:a cohort study. J. Acquir. Immune Defic. Syndr. 2000 24 : 211 17.
62. Soriano V, Maida I, Nunez M et al. Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies. Antivir. Ther. 2004 9 : 987 92.
63. Barreiro P, Labarga P, Martin-Carbonero L et al. Sustained virological response following HCV therapy is associated with non-progression of liver fibrosis in HCV/HIV-coinfected patients. Antivir. Ther. 2006 11 : 869 77.
64. Soriano V, Puoti M, Sulkowski M et al. Care of patients with hepatitis C and HIV coinfection. AIDS 2004 18 : 1 12.
65. Torriani FJ, Rodriguez-Torres M, Rockstroh JK et al. Peginterferon Alpha-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N. Engl. J. Med. 2004 351 : 438 50.
66. Carrat F, Bani-Sadr F, Pol S et al. Pegylated interferon alpha-2b vs standard interferon alpha-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004 292 : 2839 48.
67. Chung RT, Andersen J, Volberding P et al. Peginterferon Alpha-2a plus ribavirin versus interferon alpha-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N. Engl. J. Med. 2004 351 : 451 9.
68. Laguno M, Murillas J, Blanco JL et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for treatment of HIV/HCV coinfected patients. AIDS 2004 18 : F27 36.
69. Alvarez D, Dieterich DT, Brau N, Moorehead L, Ball L, Sulkowski MS. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. J. Viral. Hepat. 2006 13 : 683 9.
70. Soriano V, Puoti M, Sulkowski M et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007 21 : 1073 89.
71. Crespo M, Esteban JI, Ribera E et al. Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV coinfected patients. AIDS 2007 21 : 477 81.
72. Soriano V, Barreiro P, Nunez M. Management of chronic hepatitis B and C in HIV-coinfected patients. J. Antimicrob. Chemother. 2006 57 : 815 18.
73. Lafeuillade A HG, Chapadaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001 357 : 280 1.
74. Fleischer R, Boxwell D, Sherman KE. Nucleoside analogues and mitochondrial toxicity. Clin. Infect. Dis. 2004 38 : e79 80.
75. Laguno M, Blanch J, Murillas J et al. Depressive symptoms after initiation of interferon therapy in human immunodeficiency virus-infected patients with chronic hepatitis C. Antivir. Ther. 2004 9 : 905 9.
76. Mauss S, Valenti W, DePamphilis J et al. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS 2004 18 : F21 5.
77. Dore GJ, Torriani FJ, Rodriguez-Torres M et al. Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus coinfection. AIDS 2007 21 : 1555 9.
78. Martin-Carbonero L, Nuñez M, Mariño A et al. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C. AIDS 2008 22 : 15 21.
79. Fuster D, Planas R, Gonzalez J et al. Results of a study of prolonging treatment with pegylated interferon-alpha2a plus ribavirin in HIV/HCV-coinfected patients with no early virological response. Antivir. Ther. 2006 11 : 473 82.
80. Vento S, Garofano T, Renzini C, Casali F, Ferraro T, Concia E. Enhancement of hepatitis C virus replication and liver damage in HIV- coinfected patients on antiretroviral combination therapy. AIDS 1998 12 : 116 17.
81. Chung RT, Evans SR, Yang Y et al. Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in coinfected subjects. AIDS 2002 16 : 1915 23.
82. Fialaire P, Payan C, Vitour D et al. Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection. J. Infect. Dis. 1999 180 : 574 5.
83. Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JM. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J. Infect. Dis. 2002 186 : 23 31.
84. den Brinker M, Wit FW, Wertheim-van Dillen PM et al. Hepatitis B and C virus coinfection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000 14 : 2895 902.
85. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000 283 : 74 80.
86. Martinez E, Blanco JL, Arnaiz JA et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001 15 : 1261 8.
87. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002 35 : 182 9.
88. Kandula VR, Khanlou H, Farthing C. Tipranavir: a novel second-generation nonpeptidic protease inhibitor. Expert Rev. Anti. Infect. Ther. 2005 3 : 9 21.
89. Dore GJ. Antiretroviral therapy-related hepatotoxicity: predictors and clinical management. In : G Dore J Sasadeusz, eds. Coinfection HIV & Viral Hepatitis: A Guide for Clinical Management. Sydney : Australian Society for HIV Medicine, 2003 27 32.
90. Pineda JA, Romero-Gomez M, Diaz-Garcia F et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology 2005 41 : 779 89.
91. Neff GW, Bonham A, Tzakis AG et al. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl. 2003 9 : 239 47.
92. Ragni MV, Belle SH, Im K et al. Survival of human immunodeficiency virus-infected liver transplant recipients. J. Infect. Dis. 2003 188 : 1412 20.
93. Rufi G, Barcena R, Vargas V, the Spanish OLT-HIV Working Group. Orthotopic liver transplantation in 15 HIV-1-infected recipients: evaluation of Spanish experience in the HAART Era (2002-2003). In: 11th Conference on Retroviruses and Opportunistic Infections; San Francisco, USA, 2004.